# A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease

> **NCT06944522** · PHASE3 · RECRUITING · sponsor: **BlueRock Therapeutics** · enrollment: 102 (estimated)

## Conditions studied

- Parkinsons Disease (PD)

## Interventions

- **BIOLOGICAL:** bemdaneprocel
- **PROCEDURE:** Sham surgery

## Key facts

- **NCT ID:** NCT06944522
- **Lead sponsor:** BlueRock Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-17
- **Primary completion:** 2027-03
- **Final completion:** 2032-03
- **Target enrollment:** 102 (ESTIMATED)
- **Last updated:** 2026-05-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06944522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06944522, "A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06944522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*